Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin

NCT02420691 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02420691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02420691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 25, 2015
Completion date
June 5, 2019
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced digestive system neuroendocrine neoplasm, duodenal neuroendocrine tumor g1, functional pancreatic neuroendocrine tumor, gastric neuroendocrine tumor, intermediate grade lung neuroendocrine neoplasm, low grade lung neuroendocrine neoplasm, nonfunctional pancreatic neuroendocrine tumor, thymus neoplasm